Gaucher type 1 splits payer economics by route: IV enzyme replacement routes to Part B buy-and-bill at ~$300K a year, while oral therapies route to Part D — and the CYP2D6 gate plus generic miglustat reshape utilization management.
The three enzyme replacement therapies, imiglucerase (Cerezyme), velaglucerase alfa (VPRIV), and taliglucerase alfa (Elelyso), are physician-administered intravenous infusions and route through the Medicare Part B medical benefit under buy-and-bill, not Part D. Annual ERT cost is approximately $300,000 per patient, placing Gaucher among the highest-cost chronic therapies in US medicine. Commercial payers cover all three as medically necessary for confirmed type 1 disease (enzyme deficiency or biallelic GBA1 variant plus anemia, thrombocytopenia, organomegaly, or bone disease), and several designate imiglucerase and velaglucerase as preferred, positioning taliglucerase as a non-preferred alternative.
The oral substrate reduction therapies route differently. Eliglustat (Cerdelga) launched in 2014 at an annual WAC of $310,250 and dispenses through the Part D pharmacy benefit; its prior authorization requires a diagnosis of type 1 plus documented CYP2D6 extensive, intermediate, or poor metabolizer status by an FDA-cleared test — a genotype gate that functions as a built-in utilization-management lever. Miglustat (Zavesca) is reimbursed narrowly, for mild-to-moderate patients for whom ERT is not an option, and payers increasingly require a trial of generic miglustat first. The net payer picture is a mature orphan market where cost control comes through channel routing, step edits, preferred-ERT designation, and generic substitution rather than head-to-head price competition.
US Gaucher type 1 agent payer status — routing, cost and PA
| Drug (Brand / INN) | Mechanism / Route | Benefit Routing | Approx. Annual Cost | PA Criteria (Commercial) |
|---|---|---|---|---|
| Cerezyme (imiglucerase) | IV enzyme replacement | Medicare Part B (buy-and-bill) | ~$300,000 | Confirmed type 1 (enzyme or biallelic GBA1) + anemia / thrombocytopenia / organomegaly / bone disease; often preferred ERT |
| VPRIV (velaglucerase alfa) | IV enzyme replacement | Medicare Part B (buy-and-bill) | ~$300,000 | Same clinical criteria; frequently designated preferred ERT |
| Elelyso (taliglucerase alfa) | IV enzyme replacement | Medicare Part B (buy-and-bill) | ~$300,000 | Same clinical criteria; typically non-preferred alternative |
| Cerdelga (eliglustat) | Oral substrate reduction | Medicare Part D | $310,250 | Type 1 + CYP2D6 extensive / intermediate / poor metabolizer by FDA-cleared test |
| Zavesca (miglustat) | Oral substrate reduction | Medicare Part D | Generic available | Mild–moderate type 1 when ERT not an option; generic miglustat trial often required |
Sources: UnitedHealthcare and Blue Cross Blue Shield Gaucher ERT medical coverage policies (2025–2026); Cerdelga launch WAC per Boston Globe 2014; FDA prescribing information (Cerdelga, Zavesca); FDA Drugs@FDA.
What this assessment answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- Part B vs Part D benefit-category split
- buy-and-bill vs pharmacy dispensing
- site-of-care and OOP implications for IV vs oral therapy
Delivers
- Commercial PA criteria for ERT and SRT
- the CYP2D6 metabolizer requirement for eliglustat
- ERT-not-an-option and generic-miglustat-first requirements for miglustat
Delivers
- Preferred vs non-preferred ERT designation
- generic miglustat's low-end anchor
- orphan pricing dynamics and the main payer cost-control levers
Custom assessment delivered in 72 hours.
Commission This AssessmentWhat's inside
- All three IV enzyme replacement therapies route through Medicare Part B under buy-and-bill, while oral agents dispense through Part D
- Commercial payers cover ERT as medically necessary for confirmed type 1 disease: enzyme deficiency or biallelic GBA1 variant plus anemia, thrombocytopenia, organomegaly or bone disease
- IV enzyme replacement therapies route to the Part B medical benefit (buy-and-bill) while eliglustat and miglustat route to the Part D pharmacy benefit
- Eliglustat launched in 2014 at an annual WAC of $310,250 dispensed through Part D, a distinct site-of-care and OOP profile from the infused ERTs
- Annual ERT cost runs approximately $300,000 per patient, placing Gaucher among the highest-cost chronic therapies in US medicine
- Several payers designate imiglucerase and velaglucerase alfa as preferred ERT, positioning taliglucerase alfa as the non-preferred alternative
- Prior authorization for ERT requires confirmed type 1 diagnosis by enzyme assay or biallelic GBA1 variant, plus anemia, thrombocytopenia, organomegaly or bone disease
- Utilization management differs sharply between the three medically-necessary ERTs and eliglustat's genotype-gated, Part D prior-authorization pathway
- Eliglustat's prior authorization requires documented CYP2D6 extensive, intermediate or poor metabolizer status by an FDA-cleared test, a genotype gate that functions as built-in utilization management
- Payers increasingly require a trial of generic miglustat before considering other options for mild-to-moderate patients where ERT is not appropriate
- Cost control in this mature orphan market comes through channel routing, step edits and preferred-ERT designation rather than head-to-head price competition
- Generic miglustat substitution is the market's primary price-competition lever, since none of the three branded ERTs face generic entry
Included with every brief
How AXLRx builds this assessment
Prepared by MoatRx analysts.
Every AXLRx assessment is built from primary regulatory sources (FDA Drugs@FDA, ClinicalTrials.gov), peer-reviewed literature, and live payer and HTA documentation — not secondary summaries, market-research reports, or unverified estimates. Findings are independently verified before inclusion; if a figure cannot be sourced to a live record, it does not ship.
US Gaucher Payer & HTA sources: CMS Part B vs Part D benefit-category rules, UnitedHealthcare and Blue Cross Blue Shield Gaucher ERT medical coverage policies (2025–2026), the Cerdelga and Zavesca FDA prescribing information, and contemporaneous WAC reporting (Boston Globe 2014).
- Part B vs Part D routing verified against CMS benefit-category rules for physician-administered infusions vs oral agents and payer medical/pharmacy policies
- Commercial PA criteria and preferred-ERT designation verified against UnitedHealthcare and Blue Cross Blue Shield Gaucher coverage policies (2025–2026)
- Eliglustat CYP2D6 prior-authorization gate verified against the Cerdelga FDA prescribing information and payer policy
- Eliglustat launch WAC ($310,250) verified against contemporaneous reporting (Boston Globe 2014)
Frequently asked questions
Commission this assessment
AXLRx Gaucher Payer & HTA is built for market access, HEOR, and pricing teams navigating Part B/D routing, PA criteria, and the oral-versus-IV cost picture in the US Gaucher market. Custom assessment in 72 hours.
Specify indication, payer focus (routing, PA criteria), and commercial question.
AXLRx analyst confirms payer scope, cost data, and delivery format.
Research-verified assessment in 72 hours with optional analyst readout.